Tirzepatide dosage in units: reading the numbers on your pen

You've seen the word 'units' and now you're second-guessing your pen

It's a genuinely common point of confusion. For decades, insulin has been prescribed and measured in 'units', a pharmacological unit calibrated specifically to insulin's activity. Syringes for insulin are marked in those units, and people who manage diabetes sometimes use both insulin and a GLP-1 medicine like tirzepatide, which is why the two systems end up in the same conversation.

Tirzepatide, sold in the UK as Mounjaro, uses a completely different measurement: milligrams of the active molecule. The six licensed strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg) describe the amount of tirzepatide in each weekly dose. There is no conversion to insulin units, because the two drugs work through entirely different mechanisms and are not related pharmacologically. The NHS medicines page for tirzepatide makes clear that it is a dual GIP and GLP-1 receptor agonist, activating two gut-hormone pathways to reduce appetite and slow gastric emptying. Insulin units have no relevance here.

The KwikPen is pre-filled and pre-set. You do not draw up a dose, you do not dial in a number of units, and you do not need to calculate anything. One press of the button delivers the entire prescribed dose. That design is deliberate: it removes the calibration step entirely and with it the risk of a dosing error.

What the tirzepatide dosage schedule actually looks like

The starting dose in the licensed schedule is 2.5 mg. Its job is to settle your system, nausea and other gastrointestinal side effects are most likely early on, and beginning at the lowest strength gives your body time to adjust before any therapeutic work is expected of the medicine.

From there, the prescriber may increase the dose in 2.5 mg steps, roughly every four weeks, based on how well the medicine is tolerated and how treatment is progressing. The maximum licensed dose is 15 mg. Not everyone reaches it; many people find meaningful results at intermediate doses. The full picture of how each strength relates to outcomes is covered in our tirzepatide dosage guide, which includes what clinical trials reported at different points in the schedule.

One thing worth knowing: each KwikPen contains four weekly doses, so a single pen lasts one month. The pen's strength is printed clearly on the label, 2.5 mg, 5 mg, 7.5 mg and so on. If you want to understand how any single strength looks in practical terms, the 5 mg dose page walks through what that means week to week.

The titration schedule belongs to the prescriber, not to the patient. Adjusting the pace, skipping steps or staying longer at a given dose are clinical decisions. The Patient Information Leaflet that arrives with every pen gives full detail on injection technique, rotation sites and storage. Always read it.

Why 'units' appears on some online discussions, and what to watch for

Some of the confusion around tirzepatide dosage units comes from overseas content. In the United States, compounded tirzepatide has been sold in vials requiring a syringe, where the dose is sometimes described in terms of volume (millilitres) or, incorrectly, in 'units' borrowed from insulin conventions. That framing has no place in a UK context. In the UK, tirzepatide is licensed only as the pre-filled Mounjaro KwikPen through the regulated supply chain. Compounded or vial-based preparations are not licensed here.

The MHRA has warned publicly about counterfeit and unlicensed injectable weight-loss products being sold online, some of which have caused serious harm. If a seller is describing tirzepatide in unit measurements that require a separate syringe, or offering the medicine without a clinical assessment, both are signs that the supply is not coming through the licensed UK route. You can report anything suspicious through the MHRA Yellow Card scheme.

Getting the right information about Mounjaro dosage in units from a regulated source matters. It is not a pedantic point, it is the difference between using a medicine safely and following guidance that was never written for UK patients or UK products.

Dosage, eligibility and your next step

Tirzepatide is a prescription-only medicine. The prescriber who reviews your consultation decides which dose is appropriate for you at the start of treatment, and reviews that decision before any increase. The specific dose you are on is not interchangeable between people: it reflects your individual clinical picture, tolerance and progress.

The UK private licence covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. A full eligibility overview sits on the Mounjaro information page, and if you're curious about what private treatment involves financially, our Mounjaro prices page explains what a single transparent price includes. The clinical facts around Mounjaro 5 mg (the most common early maintenance dose) are useful background reading too.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the same day it is submitted, a person, reading your answers, making a clinical judgement. If you'd like that review, check your eligibility and start your free consultation.